- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05850689
Studie av Lumateperone som tilleggsterapi i behandling av pasienter med alvorlig depressiv lidelse
En randomisert, dobbeltblind, placebokontrollert multisenterstudie for å vurdere effektiviteten og sikkerheten til Lumateperone som tilleggsterapi ved behandling av pasienter med alvorlig depressiv lidelse
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The study will be conducted in three periods:
- Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
- Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
- Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 844-434-4210
- E-post: Participate-In-This-Study1@its.jnj.com
Studiesteder
-
-
-
Cherven Bryag, Bulgaria, 5980
- Rekruttering
- Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
-
Kardzhali, Bulgaria, 6600
- Rekruttering
- Medical Center Lifemed
-
Pleven, Bulgaria, 5800
- Rekruttering
- Medical Center Medconsult-Pleven
-
Plovdiv, Bulgaria, 4004
- Rekruttering
- Medical Center Mentalcare OOD
-
Sofia, Bulgaria, 1680
- Rekruttering
- Medical Center Intermedica, OOD
-
Sofia, Bulgaria, 1510
- Rekruttering
- Medical Center Hera EOOD
-
Sofia, Bulgaria, 1202
- Rekruttering
- MHC - Sofia, EOOD
-
Sofia, Bulgaria, 1431
- Avsluttet
- University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
-
Stara Zagora, Bulgaria, 6003
- Fullført
- UMHAT Prof. Dr. St. Kirkovich AD
-
Varna, Bulgaria, 9020
- Rekruttering
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
Alabama
-
Huntsville, Alabama, Forente stater, 35801
- Rekruttering
- University of Alabama at Birmingham
-
-
California
-
Pico Rivera, California, Forente stater, 90660
- Rekruttering
- CNRI-Los Angeles, LLC
-
-
Connecticut
-
Farmington, Connecticut, Forente stater, 06030
- Rekruttering
- University of Connecticut Health Center
-
-
Florida
-
Clermont, Florida, Forente stater, 34711
- Avsluttet
- Vertex Clinical Research
-
Hialeah, Florida, Forente stater, 33012
- Suspendert
- New Life Medical Research Center, Inc.
-
Miami, Florida, Forente stater, 33122
- Rekruttering
- Premier Clinical Research Institute
-
Miami, Florida, Forente stater, 33137
- Rekruttering
- Miami Jewish Health System
-
Tampa, Florida, Forente stater, 33629
- Rekruttering
- Interventional Psychiatry of Tampa Bay
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30329
- Rekruttering
- The Emory Clinic
-
Decatur, Georgia, Forente stater, 30030
- Rekruttering
- CenExeli Research LLC
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Avsluttet
- University of Kansas Medical Center Research Institute
-
Overland Park, Kansas, Forente stater, 66210
- Rekruttering
- Collective Medical Research
-
-
Massachusetts
-
Methuen, Massachusetts, Forente stater, 01844
- Avsluttet
- ActivMed Practices and Research
-
-
Missouri
-
O'Fallon, Missouri, Forente stater, 63368
- Rekruttering
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, Forente stater, 08755
- Rekruttering
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, Forente stater, 11235
- Rekruttering
- SPRI Clinical Trials, LLC
-
New York, New York, Forente stater, 10036
- Rekruttering
- Manhattan Behavioral Medicine
-
-
Ohio
-
Avon Lake, Ohio, Forente stater, 44012
- Rekruttering
- Quest Therapeutics of Avon Lake
-
Cincinnati, Ohio, Forente stater, 45219
- Rekruttering
- University of Cincinnati Medical Center
-
Columbus, Ohio, Forente stater, 43210
- Rekruttering
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- University of Pennsylvania - Perelman School of Medicine
-
-
Texas
-
Houston, Texas, Forente stater, 77081
- Rekruttering
- DM Clinical Research
-
Mansfield, Texas, Forente stater, 76063
- Fullført
- Hawkins Psychiatry, PC
-
Richardson, Texas, Forente stater, 75080
- Rekruttering
- Pillar Clinical Research, LLC
-
-
Washington
-
Bellevue, Washington, Forente stater, 98007
- Rekruttering
- Northwest Clinical Research Center
-
-
-
-
-
Douai, Frankrike, 59500
- Rekruttering
- Cabinet Medical des Drs Prizac-Desbonnet Scottez
-
Nantes, Frankrike, 44093
- Rekruttering
- CHU de Nantes hotel Dieu
-
Nîmes, Frankrike, 30029
- Rekruttering
- Hopital Caremeau
-
Paris, Frankrike, 75012
- Rekruttering
- Groupe Hospitalier Pitie-Salpetriere
-
Poitiers, Frankrike, 86021
- Rekruttering
- CH Henri Laborit
-
-
-
-
-
Ahmedabad, India, 380008
- Suspendert
- Ratandeep Surgical Hospital And Endoscopy Clinic
-
Ahmedabad, India, 380009
- Suspendert
- Sushrusha Navneet Memorial Hospital
-
Ajmer, India, 305001
- Suspendert
- J L N Medical College and Attached Hospitals
-
Bikaner, India, 334001
- Rekruttering
- S P Medical College And Associated Group of Hospitals
-
Bārāmati, India, 413102
- Rekruttering
- Baramati Hospital
-
Chandigarh, India, 160012
- Rekruttering
- Post Graduate Institute of Medical Education And Research PGIMER
-
Guwahati, India, 781032
- Fullført
- Gauhati Medical College and Hospital
-
Kolhāpur, India, 416001
- Rekruttering
- Swastik Hospital
-
Nagpur, India, 440001
- Rekruttering
- KIMS-Kingsway Hospitals
-
Palsāna, India, 394315
- Rekruttering
- Divyam Hospital
-
Pune, India, 411011
- Rekruttering
- Shree Samarth Hospital
-
Rajkot, India, 360001
- Fullført
- Nagecha Hospital
-
Wardha, India, 442004
- Suspendert
- Acharya vinoba bhave rural hospital
-
-
-
-
-
Kaunas, Litauen, LT-44279
- Fullført
- Romuvos Klinika, JSC
-
Ziegzdriai, Litauen, 53136
- Fullført
- Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
-
-
-
-
-
Belgrade, Serbia, 11000
- Rekruttering
- University Clinical Center of Serbia
-
Belgrade, Serbia, 11000
- Rekruttering
- Institute of Mental Health Serbia
-
Belgrade, Serbia, 11000
- Rekruttering
- Clinical Center Dr Dragisa Misovic Dedinje
-
Kovin, Serbia, 26220
- Rekruttering
- Special Hospital for Psychiatric Diseases Kovin
-
Kragujevac, Serbia, 34000
- Rekruttering
- University Clinical Center Kragujevac
-
Kragujevac, Serbia, 34000
- Rekruttering
- University Clinical Center Kragujevac 1
-
Niš, Serbia, 18000
- Rekruttering
- University Clinical Center NIS 1
-
Niš, Serbia, 18000
- Rekruttering
- University Clinical Center NIS
-
Novi Kneževac, Serbia, 23330
- Rekruttering
- Special Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Barcelona, Spania, 08036
- Rekruttering
- Hosp. Clinic de Barcelona
-
Barcelona, Spania, 08035
- Rekruttering
- Hosp Univ Vall D Hebron
-
Madrid, Spania, 28034
- Fullført
- Hosp. Univ. Ramon Y Cajal
-
Sabadell, Spania, 08208
- Rekruttering
- Hosp.Univ.Parc Tauli
-
Zamora, Spania, 49021
- Rekruttering
- Hosp. Prov. de Zamora
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Male or female patients between the ages of 18 and 65 years, inclusive;
-
Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:
- The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
- Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
- Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
- Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
- Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-
Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
- citalopram/escitalopram
- fluoxetine
- paroxetine
- sertraline
- duloxetine
- levomilnacipran/milnacipran (if locally approved for MDD)
- venlafaxine/desvenlafaxine
- bupropion
- vilazodone
- vortioxetine
Exclusion Criteria:
-
Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
- Eating disorder;
- Substance use disorders (excluding nicotine);
- Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
- Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
-
The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
-
The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
- At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
- The patient is considered to be in imminent danger to him/herself or others.
-
The patient has a first MDE at age 60 years or older.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Matching capsules administered orally, once daily |
|
Eksperimentell: Lumateperon 42 mg
|
Lumateperone 42 mg capsules administered orally, once daily |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale
Tidsramme: Day 43
|
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms. |
Day 43
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical Global Impression Scale-Severity
Tidsramme: Day 43
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Day 43
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ITI-007-505
- ITI-007-505 (Annen identifikator: Janssen Research & Development, LLC)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .